Gerresheimer AG successfully navigated financial year 2024 with solid growth, announcing the completion of the Bormioli Pharma acquisition, expected to significantly enhance revenue and EBITDA starting in 2025.

Target Information

Gerresheimer AG is a leading systems and solutions provider within the pharmaceutical, biotech, and cosmetics industries. In the financial year 2024, the company reported revenues of EUR 2,035.9 million, an increase from EUR 1,990.5 million in 2023. The adjusted EBITDA for the same period rose to EUR 419.4 million, up from EUR 404.5 million in the prior year. The company's growth was driven by a 2.9% increase in organic sales and a 4.1% rise in adjusted EBITDA, demonstrating their operational resilience despite certain market challenges.

The company's Divisions, particularly Plastics & Devices, experienced substantial growth, particularly due to high demand for medical devices. Meanwhile, the Primary Packaging Glass Division dealt with customer destocking in the vial segment, although signs of recovery were noted towards the end of 2024. Gerresheimer’s acquisition of Bormioli Pharma, completed in December 2024, is anticipated to enhance group revenues and EBITDA significantly starting in 2025.

Industry Overview

The pharmaceutical packaging industry in Germany is experiencing transformative changes, driven by technological advancements and an increased focus on biologics and high-value drug delivery systems. The demand for innovative